Laurus Labs company profile
Company profile
Laurus Labs has 7,059 employees and is headquartered in Hyderabad, India.
Generic APIs and solid oral drug products for anti-retroviral treatments open the offering of Laurus Labs Limited, which manufactures and sells medicines and active pharmaceutical ingredients in India and internationally through its subsidiaries. Its range extends to anti-diabetic, cardiovascular, anti-asthma, ophthalmology, oncology and gastroenterology products, supplied as intermediates and finished dosages. The group also develops recombinant proteins and cell-culture media supplements free of animal-origin materials, provides drug substance, drug product and biologics development services, and offers rare disease therapeutics.
In the fiscal year ended March 2026, revenue reached INR 68.1 billion, up 22.7% from the previous year, and net profit stood at INR 8.9 billion. The company employs 7,059 people and is headquartered in Hyderabad, India, where it was incorporated in 2005.
Company facts
- Sector
- Healthcare
- Industry
- Drug Manufacturers - Specialty & Generic
- Country
- India
- Headquarters
- Jubilee Hills, 500033, Hyderabad
- Employees
- 7,059
- Chief executive
- Satyanarayana Chava
- Founded
- 2005
- Fiscal year
- April - March
- Listing
- LAURUSLABS · NSE
- Currency
- INR
- ISIN
- INE947Q01028
- Website
- lauruslabs.com
Laurus Labs and its competitors
The most similar companies by business and size
| Company | Country | Market cap | Employees | Operating margin | P/E (trailing 12 months) |
|---|---|---|---|---|---|
| Laurus LabsLAURUSLABS | India | $14.13B | 7,059 | 24.1% | 97.8 |
| Yunnan Baiyao Group000538 | China | $15.07B | 9,286 | 11.2% | 19.4 |
| Zydus LifesciencesZYDUSLIFE | India | $12.92B | 29,980 | 17.2% | 28.7 |
| PharmaEssentia6446 | Taiwan | $15.94B | 131 | 38.4% | 74.1 |
| CiplaCIPLA | India | $12.34B | 31,369 | 13.0% | 39.5 |
| Shionogi4507 | Japan | $16.75B | 6,223 | 31.6% | 11.2 |
Competitors: same or related industry, same region first, then the closest market capitalization. Market cap converted into US dollars at the latest exchange rates; P/E over the last 12 months, not shown when negative.
